Slingshot Insights

Catalyst

Slingshot members are tracking this event:

AbbVie Receives FDA Accelerated Approval of Venclexta (venetoclax) Tablets, the First BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion

Source Link:: https://news.abbvie.com/news/abbvie-receives-fda-accelerated-approval-venclexta-venetoclax-tablets-first-bcl-2-inhibitor-in-relapsedrefractory-chronic-lymphocytic-leukemia-patients-with-17p-deletion.htm

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

ABBV

100%

RHHBY

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details - Novel BCL-2 inhibitor, approved as a single agent, provided 80 percent overall response rate in Phase 2 clinical study in patients with 17p deletion(1)
- Important new treatment option for patients with difficult to treat form of CLL(2)
- The approval of Venclexta reinforces AbbVie's growing position in hematologic oncology

https://news.abbvie....

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Apr 11, 2016

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Venclexta, Venetoclax, Bcl-2 Inhibitor, Chronic Lymphocytic Leukemia Patients